Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company dedicated to the development of novel cancer therapies. The company's core mission revolves around identifying new targets for cancer drug development and advancing innovative treatments to enhance patient outcomes. Headquartered in Boca Raton, Florida, Lixte focuses on addressing unmet medical needs in oncology.

Lixte's primary product candidate is LB-100, a proprietary small-molecule compound that functions as a first-in-class inhibitor of protein phosphatase 2A (PP2A). This innovative approach aims to enhance the efficacy of both chemotherapy and immunotherapy by promoting neoantigen production, boosting T-cell proliferation, and disrupting DNA repair mechanisms in cancer cells. LB-100 is currently undergoing multiple clinical trials for solid tumors, including advanced soft tissue sarcoma, metastatic colorectal cancer, and ovarian clear cell carcinoma. Additionally, Lixte has expanded its pipeline into the radiotherapy segment of cancer care through the acquisition of Liora Technologies Europe Ltd. and its proprietary LiGHT System, an electronically controlled proton therapy platform.

Recent developments include the filing of its 2025 Annual Report on Form 10-K in March 2026, highlighting operational progress. The company expanded its ovarian clear cell cancer trial, doubling patient enrollment to 42 and adding Northwestern University's Robert H. Lurie Comprehensive Cancer Center as a second clinical site. Geordan Pursglove serves as the Chairman and CEO, having assumed the role in June 2025, with Peter Stazzone appointed as CFO in September 2025. Lixte's strategic positioning emphasizes its unique PP2A inhibition approach, which is covered by a comprehensive patent portfolio and currently faces no known direct competitors.